About the Company
cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
66
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CABA News
Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4
Alger Small Cap Growth Fund featured stocks like Cabaletta Bio, Inc. (NASDAQ:CABA) in its Q4 2023 investor letter. Headquartered in Philadelphia, Pennsylvania, Cabaletta Bio, Inc. (NASDAQ ...
Cabaletta Bio CEO to Speak at Guggenheim's 6th Annual Biotech Conference
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA), a leader in the biotechnology space, has announced that its Chief Executive Officer, Dr. Steven Nichtberger, will participate in a fireside ...
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell ...
Cabaletta Bio Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Cabaletta Bio, Inc. Common Stock (CABA)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell ...
Cabaletta Bio Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Cabaletta Bio, Inc. Common Stock (CABA)
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on ...
Cabaletta Bio Inc (CABA)
PHILADELPHIA - Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotech company, has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its ...
Loading the latest forecasts...